DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hyperopia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHyperopia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hyperopia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
myelin regulatory factor (MYRF) — MYRF is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5YHU · 1.85 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
No drug is tested or proposed for hyperopia in these abstracts. The 2007 review of childhood hyperopia management reports that optometrists and ophthalmologists disagree on when to prescribe spectacles, and that no randomised controlled trials exist to validate any prescribing threshold. The author calls directly for such trials.
Three surgical case series describe mechanical correction of hyperopia. In 2005, 42 eyes (22 patients) received angle-supported phakic intraocular lenses; mean spherical equivalent fell from +6.61 D preoperatively to +0.38 D at 12 months, with 81% of eyes within ±1 D of target. Complications included night halos (10%), pupil ovalisation (7%), pupillary block (7%), anterior subcapsular opacity (5%), and iridocyclitis (5%). Endothelial cell loss at 12 months was 6%. In 2015, 42 eyes (21 patients) underwent photorefractive keratectomy with mitomycin-C; mean spherical equivalent went from +2.00 D to +0.1 D at 12 months, 69% of eyes were within ±0.50 D of emmetropia, and 43% achieved 20/20 uncorrected acuity. Three eyes lost two lines of best-corrected visual acuity. In 2021, 54 patients received femtosecond-assisted LASIK; spherical equivalent reduced from +2.15 D to +0.08 D at 12 months, and uncorrected acuity improved from 20/93 to 20/28. Two patients lost two or more lines of corrected acuity.
A 2022 review summarises that surgical choice depends on refractive error, age, and individual anatomy, and that a complete risk-benefit assessment is needed per patient. No randomised comparison of these surgical methods exists in these abstracts. What is still missing is any randomised controlled trial comparing spectacle prescribing thresholds in children, any head-to-head trial of the three surgical techniques, and any data on long-term outcomes beyond one year. Patient stratification by age, baseline accommodation, or corneal thickness is not tested in a controlled design.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Optometry and Vision Science · 2007 · 44 citations
Management of Childhood Hyperopia: A Pediatric Optometrist's Perspective
AbstractPURPOSE: To provide an optometric perspective on the management of hyperopia in children without strabismus or amblyopia. METHODS: Factors that have potentially shaped optometry's viewpoint and influenced its prescribing philosophy for childhood hyperopia, such as optometry school and residency training, professional association clinical guidelines, conferences and continuing education courses, textbooks, scientific studies, opinions of professional leaders, and clinical experiences are discussed. RESULTS: Variations in prescribing patterns for childhood hyperopia occur within optometry and within ophthalmology. There are also differences in prescribing philosophies between the two professions. These differences are probably due to a greater level of concern, more so among optometrists, about associated vision functions such as accommodation, vergence, and stereopsis, as well as concerns about the potential impact of uncorrected hyperopia on reading and school performance. CONCLUSIONS: If indications for prescribing spectacles for children with hyperopia are to be validated, randomized controlled trials need to be performed.
Journal of Cataract & Refractive Surgery · 2005 · 9 citations
Angle-supported phakic intraocular lenses in hyperopia
AbstractPURPOSE: To evaluate the efficacy and safety of angle-supported phakic intraocular lenses (PIOLs) in hyperopia. SETTING: Private practice, Siena, Italy. METHODS: A prospective noncomparative single-surgeon interventional case series comprised 42 consecutive hyperopic eyes of 22 patients having implantation of a type PIOL (Morcher) through a sclero-corneal 5.5 mm x 3.0 mm tunnel along the steepest meridian, with surgical iridectomy. The mean preoperative defocus equivalent (DEQ) was 7.30 diopters (D) +/- 1.89 (SD). The mean spherical equivalent (SE) was 6.61 +/- 1.47 D (range 4.0 to 10.5 D), and the mean refractive astigmatism was 1.51 +/- 1.33 D (range 0 to 5 D). The mean age was 29.9 +/- 6.0 years (range 22 to 42 years). Thirteen patients (59%) were men. RESULTS: Postoperative mean SE was 0.38 +/- 0.52 D (range 0 to 2 D); mean DEQ 0.93 +/- 0.98 D; mean astigmatism 0.95 +/- 1.17 D; mean surgically induced astigmatism (vector analysis) 0.67 +/- 0.58 D (95% confidence interval, 0.49-0.85); 38 eyes (90%) were within +/-2 D of DEQ, 34 eyes (81%) within +/-1 D, and 24 eyes (57%) within +/-0.5 D. Safety index was 1.05; efficacy index 0.85. Complications were night halos 10%; pupil ovalization 7%; pupillary block reversed by neodymium:YAG laser 7%; monocular anterior subcapsular opacity 5%; monocular iridocyclitis 5%; and intraocular pressure rise due to topical steroids 2%. Endothelial cell loss at 12 month was 6% (range +2.5% to -11%). CONCLUSION: High hyperopia was corrected safely and predictably by an angle-supported PIOL with limited complications.
Middle East African Journal of Ophthalmology · 2015 · 8 citations
One year outcomes of photorefractive keratectomy with the application of mitomycin-C in the treatment of mild to moderate hyperopia
AbstractPURPOSE: To evaluate refractive and visual outcomes of photorefractive keratectomy with mitomycin-C. (PRK-MMC) for the treatment of mild to moderate hyperopia. MATERIALS AND METHODS: This case series enrolled 21 patients with up to +5.50 diopters (D) of hyperopia. All 42 eyes were treated with the Concerto (Wavelight) or the Technolas 217-Z (Bausch and Lomb) excimer laser. Outcome measures included best corrected distance vision acuity (BCVA) and uncorrected distance vision correction and refraction at 1, 3, 6, and 12 months postoperatively. RESULTS: Mean patient age was 44.8 ± 11.3 years. Preoperatively, mean manifest refractive spherical equivalent (MRSE) was + 2.00 D ± 0.76 D and mean spherical refractive error was + 2.57 D ± 0.87 D (range, +1.25 D to + 5.50 D). At 12 months postoperatively, mean MRSE was + 0.1 D ± 0.61 D. MRSE was within ± 0.50 D of emmetropia in 29 eyes (69%), and 18 eyes (43%) had 20/20 uncorrected distant visual acuity. BCVA increased by two lines or more in three eyes (7.1%) and one line in two eyes (4.7%); 31 eyes showed no change, three eyes (7.1%) lost one line, and three other eyes (7.1%) lost two lines of BCVA. No eyes lost more than two lines of BCVA. Complications included Grade 2 peripheral haze in two eyes which cleared by 12 months postoperatively. CONCLUSION: PRK-MMC was a safe and predictable method for the correction of mild to moderate hyperopia.
Journal of College of Physicians And Surgeons Pakistan · 2021 · 3 citations · open access
Assessment of Refractive Outcomes of Femtosecond-assisted Laser in Situ Keratomileusis (LASIK) for Hyperopia
AbstractOBJECTIVE: To determine the effect of refractive treatment in terms of safety, efficacy, stability, accuracy, and predictability with Wavefront Optimized Laser-assisted in situ keratomileusis (LASIK) on hyperopia. STUDY DESIGN: Descriptive, analytical study. PLACE AND DURATION OF STUDY: Armed Forces Institute of Ophthalmology, National University of Medical Sciences, Rawalpindi, Pakistan from August 2013 to June 2018. Methodology: Participants were selected after detailed history, careful ocular examination and meticulous relevant assessment on refractive scans. Preoperative measurements were recorded. Refractive strategy was designed, considering individual requirements for each patient. Postoperative readings were taken at 1 day, 1 week, 1, 3, 6 and 12 months. RESULTS: A total of 54 patients participated with mean age of 28.07 + 8.13 years. Out of the 54 patients, 33 (61%) were males and 21 (39%) were females. Uncorrected distance visual acuity (UDVA) and Spherical equivalent (SEQ), which is algebraic sum of sphere and half of cylinder, were recorded pre- and postoperatively. These parameters were changed significantly at 12 months (p <0.001). SEQ reduced from 2.146 + 2.027 to 0.079 ± 0.269 Diopter (D) (p <0.001). UDVA improved from 0.672 ± 0.270 (20/93) to 0.153 ± 0.182 (20/28) (p <0.001). A total of 48 (out of 54) patients had uncorrected vision better than 20/40; and 49 patients showed either same or gain of Snellen lines when pre- and postoperative corrected distance visual acuity (CDVA) was compared. Two patients showed loss of two or more lines. All the patients had postoperative SEQ within + 1.0 D range. CONCLUSION: LASIK, performed to correct hyperopia, demonstrated satisfactory outcomes in terms of safety, efficacy, stability, accuracy, and predictability. LASIK is an effective treatment option for moderate (<6 D) hyperopia. Key Words: LASIK, Refractive surgery, Hyperopia, Spherical equivalent, Uncorrected distance visual acuity.
OphthaTherapy Therapies in Ophthalmology · 2022 · 1 citations · open access
Choosing the right surgical treatment for hyperopia
AbstractSeveral aspects make the treatment of hyperopia and selecting the treatment method challenging. This article has reviewed the main surgical options for hyperopia and factors that must be considered when choosing the right treatment. The modern refractive technology offers excellent options with the optimal choice of procedure being dependent on the level of refractive error, age of the patient and the unique anatomical factors in each case. Surgeons must perform a complete evaluation and risk-benefit assessment of the individual patient to select the best procedure.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
